Download the white paper Oncology remains the dominant focus in biopharmaceutical R&D, accounting for nearly 40% of the global pipeline. Yet development costs regularly exceed $2 billion per approved therapy, and preclinical predictability remains a persistent challenge. Part of that
White Paper: Accelerate IL-23 Drug Development with Translational Psoriasis Models ChemPartner provides integrated translational models designed to evaluate biologics and small molecules targeting the IL-23 pathway. Our capabilities span biochemical binding assays, pathway-specific cellular systems, primary immune cell models, and
START YOUR JOURNEY